Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment

Scandinavian Journal of Immunology

Volumn 68, Issue 6, 2008, Pages 616-623

  Milano, F ^a   Jorritsma, T ^a   Rygiel, A M ^a   Bergman, J J ^a   Sondermeijer, C ^a   Ten Brinke, A ^a   Vanham, S M ^a   Krishnadath, K K ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR1; CXCL3 CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GRANZYME B; GROWTH FACTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PERFORIN; PROTEINASE INHIBITOR; PROTEINASE INHIBITOR 9; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR IMMUNOLOGY; UPREGULATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2; CYTOKINES; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; RNA; TUMOR ESCAPE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55349086931     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02183.x     Document Type: Article

References (38)

1. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007 25 : 267 96.
2. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007 6 : 1186 97.
3. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004 22 : 531 62.
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001 357 : 539 45.
5. Ding MX, Lin XQ, Fu XY, Zhang N, Li JC. Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma. World J Gastroenterol 2006 12 : 4582 5.
6. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005 175 : 5351 7.
7. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996 2 : 1096 103.
8. Sombroek CC, Stam AG, Masterson AJ et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 2002 168 : 4333 43.
9. Jongmans W, Tiemessen DM, van Vlodrop IJ, Mulders PF, Oosterwijk E. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother 2005 28 : 480 7.
10. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999 189 : 1363 72.
11. Menetrier-Caux C, Montmain G, Dieu MC et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998 92 : 4778 91.
12. O'Riordain MG, Falconer JS, Maingay J, Fearon KC, Ross JA. Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. Int J Oncol 1999 15 : 823 7.
13. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005 5 : 263 74.
14. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 2003 27 : 999 1008 discussion 1006-8.
15. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001 29 : e45.
16. Villanacci V, Rossi E, Zambelli C et al. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus. Dig Liver Dis 2007 39 : 305 11.
17. Cook EB, Stahl JL, Lowe L et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods 2001 254 : 109 18.
18. Mobius C, Freire J, Becker I et al. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 2007 31 : 1768 72.
19. Oyama T, Ran S, Ishida T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998 160 : 1224 32.
20. Lagarde SM, ten Kate FJ, Richel DJ, Offerhaus GJ, van Lanschot JJ. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 2007 14 : 977 91.
21. Alici S, Ugras S, Bayram I, Izmirli M. Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma. Adv Ther 2006 23 : 672 9.
22. Liu JF, Jamieson G, Wu TC, Zhang SW, Wang QZ, Drew P. Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus. Dis Esophagus 2006 19 : 350 4.
23. Bruna A, Darken RS, Rojo F et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007 11 : 147 60.
24. Broderick L, Bankert RB. Membrane-associated TGF-beta1 inhibits human memory T cell signaling in malignant and nonmalignant inflammatory microenvironments. J Immunol 2006 177 : 3082 8.
25. Koliopanos A, Friess H, di Mola FF et al. Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 2002 26 : 420 7.
26. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000 164 : 3596 9.
27. Frumento G, Rotondo R, Tonetti M, Ferrara GB. T cell proliferation is blocked by indoleamine 2,3-dioxygenase. Transplant Proc 2001 33 : 428 30.
28. Wente MN, Keane MP, Burdick MD et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 2006 241 : 221 7.
29. Ren Y, Cao B, Law S et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 2005 11 : 6190 7.
30. Savage SA, Abnet CC, Mark SD et al. Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2004 13 : 2251 7.
31. O'Riordan JM, Abdel-latif MM, Ravi N et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia- adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005 100 : 1257 64.
32. Fitzgerald RC, Abdalla S, Onwuegbusi BA et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002 51 : 316 22.
33. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006 4 : 48.
34. Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA, Fearon KC. Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 2006 95 : 1568 75.
35. Uenaka A, Wada H, Isobe M et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 2007 7 : 9.
36. Medema JP, Schuurhuis DH, Rea D et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 2001 194 : 657 67.
37. Dvorakova K, Payne CM, Ramsey L et al. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 2004 10 : 2020 8.
38. Dvorak K, Chavarria M, Payne CM et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus. Clin Cancer Res 2007 13 : 5305 13.